- Associated Press•14 minutes ago
On a per-share basis, the Basel, Switzerland-based company said it had net income of 81 cents. Earnings, adjusted for non-recurring costs, were $1.23 per share. The results surpassed Wall Street expectations. ...
- Reuters•37 minutes ago
Novartis' struggling Alcon eye care division will take longer to turn around than expected, the Swiss drugmaker's Chief Executive Joe Jimenez warned on Tuesday as he reported a smaller than forecast fall in third quarter net income. Alcon's sales this quarter will be "flat to down slightly," Jimenez said, after predicting earlier this year that the division's new head Michael Ball would have it growing at a low-single-digit percentage rate by the year-end. Novartis has blamed a failure to innovate and inconsistent customer service for the problems at Alcon, a business the company gradually bought from food maker Nestle in deals totalling $51 billion, but could eventually sell.
- Associated Press•1 hour ago
FRANKFURT, Germany (AP) — Swiss drug company Novartis saw net profit slip in the third quarter as the loss of a key drug to generic use in the United States outweighed strong sales of its psoriasis drug Cosentyx and MS treatment Gilenya.
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||73.96 x 4000|
|Ask||74.03 x 4000|
|Day's Range||74.78 - 75.89|
|52wk Range||69.90 - 91.88|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||26.94|
|Avg Vol (3m)||1,680,170|
|Dividend & Yield||2.72 (3.60%)|